Analyzing Black Titan (BTTC) & Its Competitors

Black Titan (NASDAQ:BTTC) is one of 48 publicly-traded companies in the “Services – Computer Programming And Data Processing” industry, but how does it contrast to its peers? We will compare Black Titan to similar companies based on the strength of its profitability, dividends, risk, valuation, earnings, institutional ownership and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Black Titan and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Titan	1	0	0	0	1.00
Black Titan Competitors	100	197	218	12	2.27

As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 120.15%. Given Black Titan’s peers stronger consensus rating and higher probable upside, analysts clearly believe Black Titan has less favorable growth aspects than its peers.

Profitability

This table compares Black Titan and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Titan	N/A	-108.60%	-95.64%
Black Titan Competitors	-51.08%	-912.69%	-63.05%

Valuation & Earnings

This table compares Black Titan and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Black Titan	$180,000.00	-$4.71 million	-0.58
Black Titan Competitors	$255.93 million	-$53.25 million	-11.65

Black Titan’s peers have higher revenue, but lower earnings than Black Titan. Black Titan is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Black Titan has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s peers have a beta of 0.68, suggesting that their average stock price is 32% less volatile than the S&P 500.

Insider & Institutional Ownership

57.5% of shares of all “Services – Computer Programming And Data Processing” companies are held by institutional investors. 53.7% of Black Titan shares are held by company insiders. Comparatively, 20.5% of shares of all “Services – Computer Programming And Data Processing” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Black Titan peers beat Black Titan on 7 of the 12 factors compared.

Black Titan Company Profile

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.